Loading...
Market
Will Starboard Value install a new board member at Pfizer by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Pfizer's official announcements and filings with the SEC
Story
Ex-Pfizer CEO Read and CFO D'Amelio Back CEO Bourla, Exit Starboard's Activist Campaign
Oct 10, 2024, 01:31 AM
Former Pfizer CEO Ian Read and former CFO Frank D'Amelio have withdrawn their support for activist investor Starboard Value's campaign against Pfizer, declaring they are "fully supportive" of current CEO Albert Bourla, senior management, and the board. The two executives had initially teamed up with Starboard to address Pfizer's lack of focus, but their unexpected reversal leaves the activist campaign struggling without backing from former company insiders. This development comes as Starboard Value, which has purchased $1 billion worth of Pfizer shares, has been increasing pressure on the pharmaceutical giant following concerns over its performance after the COVID-19 crisis. Investors note that Pfizer offers a dividend yield of 5.5%, making it attractive to some despite recent challenges.
View original story
Similar markets
Increased R&D investment • 25%
New product launches • 25%
Cost-cutting measures • 25%
Other strategic changes • 25%
Increases stake • 25%
Maintains stake • 25%
Reduces stake • 25%
Exits stake • 25%
Major restructuring • 25%
New strategic initiatives • 25%
Minor adjustments • 25%
No significant changes • 25%
Yes • 50%
No • 50%
Cost-cutting measures • 25%
New product focus • 25%
Management restructuring • 25%
Other • 25%
Albert Bourla steps down • 25%
Starboard gains board seats • 25%
No significant changes • 25%
Other outcomes • 25%
Starboard gains board seats • 25%
Starboard withdraws campaign • 25%
No significant changes • 25%
Other outcomes • 25%